BACKGROUND: Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term. METHOD: This retrospective analysis of data from a 28-week, double-blind, schizophrenia trial compared the cumulative amount of time that patients met severity criteria for remission during olanzapine (10-20 mg/day) orrisperidone (4-12 mg/day) treatment. RESULTS: The percentage cumulative time spent in remission was 40% for olanzapine- and 31% for risperidone-treated patients (P = 0.03) using Definition 1 (PANSS items P1, P2, P3, N1, N4, N6, G5, G9 < or = 3), and 18% and 11% (P = 0.01), respectively, using Definition 2 (BPRS Total reduced 50%, BPRS psychosis items < or = 3, CGI-severity < or = 3). CONCLUSION: During 28 weeks of treatment, olanzapine-treated patients spent more cumulative time in remission than risperidone-treated patients.
RCT Entities:
BACKGROUND: Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term. METHOD: This retrospective analysis of data from a 28-week, double-blind, schizophrenia trial compared the cumulative amount of time that patients met severity criteria for remission during olanzapine (10-20 mg/day) or risperidone (4-12 mg/day) treatment. RESULTS: The percentage cumulative time spent in remission was 40% for olanzapine- and 31% for risperidone-treated patients (P = 0.03) using Definition 1 (PANSS items P1, P2, P3, N1, N4, N6, G5, G9 < or = 3), and 18% and 11% (P = 0.01), respectively, using Definition 2 (BPRS Total reduced 50%, BPRS psychosis items < or = 3, CGI-severity < or = 3). CONCLUSION: During 28 weeks of treatment, olanzapine-treated patients spent more cumulative time in remission than risperidone-treated patients.
Authors: Ilja Spellmann; Rebecca Schennach; Florian Seemüller; Sebastian Meyer; Richard Musil; Markus Jäger; Max Schmauß; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Michael Bauer; Mazda Adli; Joachim Zeiler; Wolfram Bender; Klaus-Thomas Kronmüller; Marcus Ising; Peter Brieger; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Michael Riedel; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-10-26 Impact factor: 5.270